Patents by Inventor John G. Gleason

John G. Gleason has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL TRAPS IN THE TREATMENT OF MACULAR DEGENERATION
    Publication number: 20190125729
    Abstract: The present invention is directed to compounds of formula (A): pharmaceutical compositions, and methods of use for treating, reducing a symptom of or reducing the risk of macular degeneration.
    Type: Application
    Filed: October 23, 2018
    Publication date: May 2, 2019
    Inventors: John Clifford Chabala, Thomas A. Jordan, Ke-Qing Ling, John G. Gleason, William A. Kinney
  • Traps in the treatment of macular degeneration
    Patent number: 10111862
    Abstract: The present invention is directed to compounds of formula (A): pharmaceutical compositions, and methods of use for treating, reducing a symptom of or reducing the risk of macular degeneration.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: October 30, 2018
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: John Clifford Chabala, Thomas A. Jordan, Ke-Qing Ling, John G. Gleason, William A. Kinney
  • NOVEL TRAPS IN THE TREATMENT OF MACULAR DEGENERATION
    Publication number: 20150344447
    Abstract: The present invention is directed to compounds of formula (A): pharmaceutical compositions, and methods of use for treating, reducing a symptom of or reducing the risk of macular degeneration.
    Type: Application
    Filed: January 21, 2014
    Publication date: December 3, 2015
    Inventors: John Clifford Chabala, Thomas A. Jordan, Ke-Qing Ling, John G. Gleason, William A. Kinney
  • Agonizing dimeric cell-surface receptors with a receptor binding moiety and chelating metal
    Publication number: 20030013697
    Abstract: Invented are metal chelated dimeric cell-surface receptor ligands, pharmaceutical compositions containing these compounds, and methods of using these compounds as agonist of dimeric cell-surface receptors. Also invented are novel processes used in preparing these compounds. Also invented are novel receptor binding moieties of the invented metal chelated cell-surface receptor ligands.
    Type: Application
    Filed: August 12, 2002
    Publication date: January 16, 2003
    Applicant: SmithKline Beecham Corporation and Ligand Pharmaceuticals
    Inventors: Juan I. Luengo, Stephen G. Miller, John G. Gleason
  • Vitronectin Receptor Antagonists
    Publication number: 20020147334
    Abstract: Compounds of the formula (1) are disclosed which are vitronectin receptor antagonists and are useful in the treatment of osteoporosis: 1
    Type: Application
    Filed: February 26, 2002
    Publication date: October 10, 2002
    Applicant: SmithKline Beecham Corporation
    Inventors: William H. Miller, John G. Gleason, Dirk Heerding, James M. Samanen, Irene N. Uzinskas, Peter J. Manley
  • Agonizing dimeric cell-surface receptors with a receptor binding moiety and chelating metal
    Patent number: 6413952
    Abstract: Dimeric cell-surface receptors in a subject are agonized by administering a metal chelated dimeric cell-surface receptor ligand formed by chelating a receptor binding moiety with a metal ion such as zinc, or by co-administering the receptor binding moiety and the metal ion. The binding moiety is a small organic molecule having a molecular weight of from about 100 to about 850, and metal chelation may form a symmetrical multimer such as a dimer of the receptor binding moiety. An example is bis{2,5-bis[2-benzimidazolylimino]-3a,6a-bis(2-pyridyl)-1,2,3,3a,4,5,6,6a-octahydroimidazo[4,5-d]imidazole-N,N′}-zinc(II). Dimeric cell surface receptors include granulocyte colony-stimulating factor, erythropoeitin receptor, macrophage-colony-stimulating factor, growth hormone receptor, thrombopoietin receptor, interferon alpha receptor, interferon beta receptor, tyrosine kinase receptor, insulin receptor and leptin receptor.
    Type: Grant
    Filed: April 29, 1999
    Date of Patent: July 2, 2002
    Assignees: SmithKline Beecham Corporation, Ligand Pharmaceuticals
    Inventors: Juan I. Luengo, Stephen G. Miller, John G. Gleason
  • Metal complexes
    Patent number: 6280959
    Abstract: The invention describes zinc chelated dimeric cell-surface receptor ligands, pharmaceutical compositions containing these compounds, methods of using these compounds as agonist of dimeric cell-surface receptors. Novel processes used in preparing the compounds are also described. Further, the invention describes novel receptor binding moieties of the zinc chelated cell-surface receptor ligands.
    Type: Grant
    Filed: April 27, 2000
    Date of Patent: August 28, 2001
    Assignee: SmithKline Beecham Corporation
    Inventors: John G. Gleason, Juan I. Luengo
  • NOVEL METAL COMPLEXES
    Publication number: 20010016568
    Abstract: Invented are zinc chelated dimeric cell-surface receptor ligands, pharmaceutical compositions containing these compounds, and methods of using these compounds as agonist of dimeric cell-surface receptors. Also invented are novel processes used in preparing these compounds. Also invented are novel receptor binding moieties of the invented zinc chelated cell-surface receptor ligands.
    Type: Application
    Filed: October 30, 1998
    Publication date: August 23, 2001
    Inventors: JUAN I. LUENGO, JOHN G. GLEASON
  • NOVEL METAL COMPLEXES
    Publication number: 20010014454
    Abstract: Invented are zinc chelated dimeric cell-surface receptor ligands, pharmaceutical compositions containing these compounds, and methods of using these compounds as agonist of dimeric cell-surface receptors. Also invented are novel processes used in preparing these compounds. Also invented are novel receptor binding moieties of the invented zinc chelated cell-surface receptor ligands.
    Type: Application
    Filed: April 27, 2000
    Publication date: August 16, 2001
    Inventors: JOHN G. GLEASON, JUAN I. LUENGO
  • Substituted histidines
    Patent number: 5565480
    Abstract: Angiotensin II receptor antagonists having the formula: ##STR1## which are useful in regulating hypertension and in the treatment of congestive heart failure, renal failure, and glaucoma, pharmaceutical compositions including these antagonists, and methods of using these compounds to produce angiotensin II receptor antagonism in mammals.
    Type: Grant
    Filed: May 2, 1995
    Date of Patent: October 15, 1996
    Assignee: SmithKline Beecham Corporation
    Inventors: John G. Gleason, Judith Hempel, David T. Hill, James Samanen, Joseph Weinstock
  • 4-phenyl-1,2-cyclohexyl derivatives and anti-inflammatory compositions and methods thereof
    Patent number: 5449687
    Abstract: Novel compounds of Formulas (I) and (II) ##STR1## are described herein. These compounds inhibit the production of Tumor Necrosis Factor and are useful in the treatment of disease states mediated or exacerbated by TNF production; these compounds are also useful in the mediation or inhibition of enzymatic or catalytic activity of phosphodiesterase IV.
    Type: Grant
    Filed: September 29, 1994
    Date of Patent: September 12, 1995
    Assignee: SmithKline Beecham Corporation
    Inventors: Siegfried B. Christensen, IV, Paul E. Bender, Cornelia J. Forster, John G. Gleason
  • Substituted histidines having angiotension II receptor antagonist activity
    Patent number: 5444081
    Abstract: Angiotensin II receptor antagonists having the formula: ##STR1## which are useful in regulating hypertension and in the treatment of congestive heart failure, renal failure, and glaucoma, pharmaceutical compositions including these antagonists, and methods of using these compounds to produce angiotensin II receptor antagonism in mammals.
    Type: Grant
    Filed: February 19, 1993
    Date of Patent: August 22, 1995
    Assignee: SmithKline Beecham Corp
    Inventors: John G. Gleason, Judith Hempel, David T. Hill, James Samanen, Joseph Weinstock
  • Leukotriene antagonists
    Patent number: 5314918
    Abstract: This invention relates to alkanoic acid compounds having phenyl and heteroarylthio substituents which are useful as leukotriene antagonists, processes for the preparation thereof, and pharmaceutical compositions containing such compounds.This invention also relates to methods of treating diseases in which leukotrienes are a factor by administration of an effective amount of the above compounds or compositions.
    Type: Grant
    Filed: April 2, 1992
    Date of Patent: May 24, 1994
    Assignee: SmithKline Beecham Corporation
    Inventors: James S. Frazee, John G. Gleason, Ralph F. Hall
  • Pyrrolo [1,2-a] imidazole and imidazo [1,2a] pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors
    Patent number: 5145858
    Abstract: Compounds comprising pyridyl and phenyl substituted pyrrolo[1,2-a]imidazole derivatives and pyridyl and phenyl substituted imidazo[1,2-a]pyridine derivatives, pharmaceutical compositions containing said compounds, and their use as 5-lipoxygenase pathway inhibitors.
    Type: Grant
    Filed: December 26, 1991
    Date of Patent: September 8, 1992
    Assignee: SmithKline Beecham Corp.
    Inventors: Jerry L. Adams, Paul E. Bender, John G. Gleason, Nabil Hanna, John F. Newton, Jr., Carl D. Perchonock
  • Leukotriene antagonists containing tetrazolyl groups
    Patent number: 5143931
    Abstract: This invention relates to alkanoic acid compounds having phenyl and heteroarylthio substituents which are useful as leukotriene antagonists and pharmaceutical compositions containing such compounds. This invention also relates to methods of treating diseases in which leukotrienes are a factor by administration of an effective amount of the above compounds or compositions.
    Type: Grant
    Filed: December 21, 1990
    Date of Patent: September 1, 1992
    Assignee: SmithKline Beecham Corporation
    Inventors: John G. Gleason, Ralph F. Hall, Irene Uzinskas
  • Leukotriene antagonists
    Patent number: 5135938
    Abstract: Leukotriene antagonist thiadiazoles have been prepared.
    Type: Grant
    Filed: March 30, 1990
    Date of Patent: August 4, 1992
    Assignee: SmithKline Beecham Corporation
    Inventors: John G. Gleason, Ralph F. Hall, Irene Uzinskas
  • Inhibition of the 5-lipoxygenase pathway
    Patent number: 5134150
    Abstract: A method of inhibiting the 5-lipoxygenase pathway in an animal in need thereof which comprises administering an effective, 5-lipoxygenase pathway inhibiting amount of a diaryl- substituted imidazole fused to a thiazole pyrrolidine, thiazide or piperidine ring to such animal.
    Type: Grant
    Filed: December 4, 1989
    Date of Patent: July 28, 1992
    Assignee: SmithKline Beecham Corporation
    Inventors: Paul E. Bender, John G. Gleason, Don E. Griswold, Nabil Hanna, Ivan Lantos, Kazys A. Razgaitis, Henry M. Sarau, Susan C. Shilcrat
  • Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors
    Patent number: 5002941
    Abstract: Compounds comprising pyridyl and phenyl substituted pyrrolo[1,2-a]imidazole derivatives and pyridyl and phenyl substituted imidazo[1,2-a]pyridine derivatives, pharmaceutical compositions containing said compounds, and their use as 5-lipoxygenase pathway inhibitors.
    Type: Grant
    Filed: October 11, 1988
    Date of Patent: March 26, 1991
    Assignee: SmithKline Beecham Corporation
    Inventors: Jerry L. Adams, Paul E. Bender, John G. Gleason, Nabil Hanna, John F. Newton, Jr., Carl D. Perchonock, Kazys Razgaitis
  • Quinolinyl substituted phenyl/thioalkanoic acid substituted propionic acids and leucotriene antagonist use thereof
    Patent number: 4996214
    Abstract: This invention covers quinolinyl substituted phenyl/thioalkanoic acid substituted propionic acids leukotriene inhibitors having the following general formula ##STR1## where the substituents are defined herein.
    Type: Grant
    Filed: June 28, 1990
    Date of Patent: February 26, 1991
    Assignee: SmithKline Beecham Corporation
    Inventors: Russell D. Cousins, James S. Frazee, John G. Gleason, Ralph F. Hall
  • Leukotriene antagonists
    Patent number: 4954513
    Abstract: This invention relates to alkanoic acid compounds having phenyl and heteroarylthio substituents which are useful as leukotriene antagonists, pharmaceutical compositions containing such compounds, and methods of treating diseases in which leukotrienes are a factor by administration of an effective amount of the above compounds or compositions.
    Type: Grant
    Filed: December 23, 1988
    Date of Patent: September 4, 1990
    Assignee: SmithKline Beecham Corporation
    Inventors: John G. Gleason, Ralph F. Hall, Joanne Smallheer